AI Startup Builds Secret Lab to Mix Robots With Biology

Anthropic has quietly opened a real biology lab in the San Francisco Bay Area. The company wants to use its AI to find cures for rare diseases that big drug firms ignore. Eric Kauderer-Abrams leads the life sciences team. He says the final test for any biology work still happens in a physical lab. The startup does some experiments in house and partners with outside labs for the rest. A spokesperson later said the lab is not strictly for drug discovery but would not give details.

The push is personal for CEO Dario Amodei. His father died from a disease just before a cure arrived. That loss drives the mission to build AI that helps humanity. Kauderer-Abrams agrees the biggest chance to do good lies in life sciences. The team wants to speed up research by letting their AI model Claude direct robotic equipment. Machines would run experiments with little human help. Still the company insists people must stay in the loop for safety.

This move happens while Anthropic faces big questions about risk. Some researchers warned their AI could one day threaten human survival. The company also found cases where its systems might aid biological weapons work. Amodei has called for a slowdown in AI development. At the same time the startup eyes a massive public offering that could value it at two trillion dollars. Kauderer-Abrams says they balance progress with caution every day.

Anthropic has been busy building its biology toolkit. In June leaders said they would tackle early research that traditional firms find unprofitable. They launched software called Claude Science for scientists. The board gained Novartis chief Vas Narasimhan. The company also bought a startup named Coefficient Bio for about four hundred million dollars in stock. All these steps show a serious bet on mixing AI with wet lab science.